RxDoctor Payments Data

Ali Yousufuddin, MD

Pain Medicine · Chambersburg, PANPI 1083607840

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 72.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $1,672 and has fallen 51.3% since, to $814 in 2025.

$7,044in general payments, 2019–2025

Across 405 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Pfizer$522
  • Collegium Pharmaceutical, Inc.$331
  • Scilex Pharmaceuticals Inc.$267
  • Daiichi Sankyo Inc.$249
  • Biodelivery Sciences International, Inc.$180
  • plus $399 from 10 others

What the payments were for

  • Food & beverage$7,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,044 in reported general payments places this provider in the 80th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$99,529
Medicare patients
114
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl38$38,407
Nucynta ErTapentadol Hcl13$23,771
LyricaPregabalin26$15,998
Buprenorphine46$14,221
MovantikNaloxegol Oxalate19$7,678
Tramadol Hcl ErTramadol Hcl62$6,269
Oxycodone Hcl257$5,240
Lidocaine26$3,785
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen161$3,477
Gabapentin235$3,442
Tramadol Hcl340$2,677
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen123$2,367
Pregabalin109$2,345
Fentanyl23$2,294
Tizanidine Hcl75$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er$331$62,17851 claims
PfizerLyrica$522$15,99826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →